Lion TCR Secures China NMPA IND Approval for GZL-016, an Innovative mRNA-based TCR-T Cell Therapy for Hepatocellular Carcinoma

Lion TCR Secures USD 40 million Series B2 Financing, Revolutionizing Solid Tumor Treatment with mRNA-Encoding TCR-T Cell Therapy

Lion TCR Clinched The "Outstanding Innovative Award" At The 2023 Cell And Gene Therapy (CGT) Asia Innovation Summit.

Lion TCR Announces Poster Presentation of Phase 1 Study for Lead Product LioCyx-M at AASLD The Liver Meeting 2022

Lion TCR Clinched ‘Most Promising Cell & Gene Therapy Startup in Asia’ Award

Cancer Immunotherapy Developers in Asia Explore Diverse Approaches

Lion TCR Receives FDA Fast Track Designation for its HBV-specific TCR T Cell Therapy for Hepatocellular Carcinoma

Scientific Founder & Chairman, Professor Antonio Bertoletti Has Been Placed on Highly Cited Researchers 2021 List

Lion TCR’s Sharing of US FDA IND Achievement at Various Conferences

Lion TCR Announces FDA Clearance of its IND Application for its Lead Investigational Product, LioCyx-M004, for Hepatocellular Carcinoma

Scientific Founder, Prof Antonio Bertoletti Appointed as Cellular Immunotherapy Infectious Diseases Lead for Singhealth Duke-NUS Cell Therapy Centre

Lion TCR Licenses and Duke-NUS Medical School ink an exclusive IP licensing agreement for Immunosuppressive Drug Resistant Anti-Cancer T-cells

Dr Wai Lu-En, Director of R&D, represented Lion TCR to share the latest developments to the Minister for Manpower and Second Minister for Trade and Industry Tan See Leng.

Scientific Founder, Prof Antonio Bertoletti Appointed in Cell and Gene Therapy Workgroup in Singapore

Lion TCR Announces Data Presentation for its lead T-cell product, LioCyx-M at EASL Digital Liver Cancer Summit 2021

HSA approval for clinical trial for Lion TCR’s lead product LioCyx-M to characterize changes in liver cancer tumor microenvironment

Lion TCR COO Dr Tina Wang’s sharing at Phar-East Asia's Pharma & Biotech Festival 2020

Lion TCR presents two abstracts of Phase 1 clinical trial data for lead product LioCyx-M at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Lion TCR was featured in the Business Times “Fighting Covid-19 with local innovations”

Lion TCR joins the efforts to develop new strategies for protection and treatment of COVID-19

Companion diagnostic assay for personalised immunotherapy for HBV-related liver cancer featured in A*STAR GIS website

Prof. Antonio Bertoletti is named Top 0.1% Hepatitis B Expert in the World

Singapore DPM Heng Swee Keat and A*STAR Chairman Chan Lai Fung visit Lion TCR

Novel treatment for liver cancer gets funding boost

Local breakthrough research in liver cancer - Cell reprogramming can kill tumors

Singapore’s first clinical trial approval for T cell engineered (TCR) immunotherapy for treatment of Liver cancer

Lion TCR receives US$ 20 million to fund its personalized T cell therapy clinical trials against Liver cancer

Scientific Founder, Prof. Antonio Bertoletti and Scientific Consultant, Dr Anthony Tanoto Tan of Lion TCR were awarded  the SingHealth Duke-NUS Research Award 1st Prize 2018

Singapore government support for global product commercialization of Lion TCR biotechnology company

US FDA grants Lion TCR two orphan drug designations of T cell therapy against Hepatocellular Carcinoma

Breakthrough immunotherapy for Chronic Hepatitis B virus infection

Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient

Dr. Antonio Bertoletti speaks at the World Life Science Conference 2016

Scientific Director, Dr. Sarene Koh, speaks at the 1st Transmed-VN Conference

Dr. Antonio Bertoletti presents Lion TCR T-cell therapy at the International Society for Cellular Therapy Conference 2016